Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App





Diasorin Launches LIAISON IQ POC Reader with 10-Minute SARS-CoV-2 Antibody Test

By LabMedica International staff writers
Posted on 22 Apr 2021
DiaSorin (‎Saluggia‎, Italy) has launched the LIAISON IQ, its new immunodiagnostic Point-of-Care (POC) reader, and the LIAISON QuickDetect COVID TrimericS Ab test, developed with Lumos Diagnostics (Sarasota, FL, USA) in countries accepting the CE Mark.

This first test available on the LIAISON IQ detects specific IgG antibodies against SARS-CoV-2 spike protein in human capillary blood from a finger stick in 10 minutes. In clinical studies, the test showed a specificity of 97.5% and a sensitivity of 98.0%. The test, which utilizes the full-length trimeric form of the SARS-CoV-2 spike protein already in use in the recently launched LIAISON SARS-CoV-2 TrimericS IgG assay, will be an important tool to establish if a patient has had an adaptive immune response to COVID-19 triggered by either a natural infection or by a vaccine.

DiaSorin intends to access this new market starting with a dedicated program in Italy, targeting pharmacies through agreements with distributors to foster capillary placements of the new combined offer of the platform and the antibody assay. Patients will be able to be tested directly in the pharmacies, with a quick time-to-result solution to detect immune response to SARS-CoV-2 with laboratory-setting quality.

The LIAISON IQ and the LIAISON Quick Detect COVID IgG Ab will also be available in the US market following the US Food and Drug Administration (FDA) Authorization. DiaSorin, together with Lumos, is also pursuing the development of a SARS-CoV-2 Antigen test to be CE marked and submitted to US FDA for Emergency Use Authorization (EUA) within Q2 2021.

“The CE Marking of our LIAISON IQ and its first test provide us access to the growing lateral flow business in the Point-of-care market, allowing DiaSorin to follow the decentralization trend of diagnostics,” said Carlo Rosa, CEO of DiaSorin Group. “This is the right timing for entering the immunodiagnostics Point-of-Care business, with a breakthrough lab-quality solution that uses our biological raw materials in a new, nearer-to-patients context. Our decentralized setting IgG test is the perfect solution to check vaccine efficacy, which is a very relevant information in the current context of the pandemic.”

Related Links:
DiaSorin
Lumos Diagnostics



Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.